{"id":5719,"date":"2020-04-03T11:21:22","date_gmt":"2020-04-03T09:21:22","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf"},"modified":"2020-04-03T11:28:23","modified_gmt":"2020-04-03T09:28:23","slug":"axial-biotherapeutics-announces-positive-topline-results-from-phase-1b-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/axial-biotherapeutics-announces-positive-topline-results-from-phase-1b-2a-clinical-trial-of-ab-2004-for-the-treatment-of-autism-spectrum-disorder\/axial-biotherapeutics-announces-positive-topline-results-from-phase-1b-2\/","title":{"rendered":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-5719","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Axial Biotherapeutics Announces Positive Topline Results from Phase 1b | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf\",\"name\":\"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2020-04-03T09:21:22+00:00\",\"dateModified\":\"2020-04-03T09:28:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b\/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder\",\"item\":\"https:\/\/www.seventure.fr\/en\/axial-biotherapeutics-announces-positive-topline-results-from-phase-1b-2a-clinical-trial-of-ab-2004-for-the-treatment-of-autism-spectrum-disorder\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf","name":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2020-04-03T09:21:22+00:00","dateModified":"2020-04-03T09:28:23+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b\/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder","item":"https:\/\/www.seventure.fr\/en\/axial-biotherapeutics-announces-positive-topline-results-from-phase-1b-2a-clinical-trial-of-ab-2004-for-the-treatment-of-autism-spectrum-disorder\/"},{"@type":"ListItem","position":3,"name":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf'><img loading=\"lazy\" decoding=\"async\" width=\"212\" height=\"300\" src=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-212x300.jpg\" class=\"attachment-medium size-medium\" alt=\"\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"sizes":{"thumbnail":{"file":"Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-106x150.jpg","width":106,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-106x150.jpg"},"medium":{"file":"Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-212x300.jpg","width":212,"height":300,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-212x300.jpg"},"large":{"file":"Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-724x1024.jpg","width":724,"height":1024,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf-724x1024.jpg"},"full":{"file":"Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf.jpg","width":1058,"height":1497,"mime_type":"application\/pdf","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b-pdf.jpg"}}},"post":5721,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/04\/Axial-Biotherapeutics-Announces-Positive-Topline-Results-from-Phase-1b.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/5719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=5719"}]}}